The Grunenthal Group
Grünenthal is a privately-owned, science-based pharmaceutical company headquartered in Aachen, Germany, focused exclusively on pain management and related diseases. It markets Movantik®, Qutenza®, and Nebido® across approximately 100 countries, with a €1.8 billion FY2024 revenue base and a proprietary NaV 1.8 inhibitor in Phase I clinical development.
- Company typePrivate
- Founded1946
- HeadquartersAachen, Germany
- Headcount1,001–5,000
- GTM typeB2B
- OfferingHardware or Manufacturing
What The Grunenthal Group does
Grünenthal Group is a privately-owned, science-based pharmaceutical company headquartered in Aachen, Germany, founded in 1946 and operating globally with approximately 4,300 employees across 28 country affiliates. The company is exclusively focused on pain management and related diseases, applying expertise in neurobiology, neuronal hyper- and hypoexcitability, sensory biology, neuronal health, and neuroinflammation to address acute and chronic pain conditions. Products are made available to patients in approximately 100 countries through direct affiliates and licensing partnerships. Leadership is led by CEO Gabriel Baertschi, with CFO Fabian Raschke, CCO Jan Adams, and CSO Uli Brödl on the executive team.
The company's commercial portfolio combines acquired established brands and proprietary pipeline assets. Core marketed products include Movantik® (naloxegol) for opioid-induced constipation—acquired in 2024 via the approximately $250 million all-stock acquisition of Valinor Pharma and generating over $200 million in US sales in 2023—Qutenza® (capsaicin), a topical non-opioid patch for peripheral neuropathic pain, and Nebido® (testosterone undecanoate) for male hypogonadism. The R&D pipeline features a proprietary orally administered voltage-gated sodium channel (NaV) 1.8 inhibitor that entered Phase I clinical trials in February 2026 with results expected in H2 2026, targeting non-opioid pain therapy. Grünenthal also holds full ownership since March 2026 of the Grünenthal Meds portfolio — 12 established brands across 6 therapeutic areas in over 60 markets, previously a joint venture with Kyowa Kirin International.
Grünenthal operates a fully integrated pharmaceutical business model, generating revenue through direct sales of branded products via field salesforces to healthcare providers, hospitals, and pharmacies, supplemented by licensing and royalty agreements with regional partners (BCWorld Pharm in South Korea, Clinect in Australia, Apotex/Searchlight Pharma in Canada). The company pursues an explicit M&A-driven growth strategy targeting established brands that deliver rapid financial returns and synergies across manufacturing, logistics, and commercial operations. FY2024 revenue was approximately €1.8 billion. Distribution infrastructure includes manufacturing sites in Switzerland (Mitlödi), Italy (Origgio), and Chile (Santiago), with regional sales and marketing offices across Europe, Latin America, and the US (Morristown and Boston).
The Grunenthal Group firmographics
Firmographics- Name
- The Grunenthal Group
- Legal name
- Grünenthal GmbH
- Website
- https://grunenthal.com
- Company type
- Private
- Founded year
- 1946
- Operating status
- Operating
- Headcount range
- 1,001–5,000 employees
- Short description
- Grünenthal is a privately-owned, science-based pharmaceutical company headquartered in Aachen, Germany, focused exclusively on pain management and related diseases. It markets Movantik®, Qutenza®, and Nebido® across approximately 100 countries, with a €1.8 billion FY2024 revenue base and a proprietary NaV 1.8 inhibitor in Phase I clinical development.
- Ownership category
- akta.pro rank
The Grunenthal Group industry classification
Industry- Product category
- Pain Management Pharmaceuticals
- NAICS
- Pharmaceutical Preparation Manufacturing (325412), Drugs and Druggists' Sundries Merchant Wholesalers (42421), Surgical Appliance and Supplies Manufacturing (339113)
- SIC
- Pharmaceutical Preparations (2834), Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122), Surgical & Medical Instruments & Apparatus (3841)
- akta.pro primary industry
- Pain Management & Anesthesiology Pharmaceuticals (HLAIAAAN)
- akta.pro secondary industries
- Pain Medicine (Interventional/Neuropathic Pain) (HLAKAIAM), Nephrology & Urology Specialty Pharmaceuticals (HLAIACAH)
Keywords
Where The Grunenthal Group is headquartered
LocationHeadquarters
- HQ city
- Aachen
- HQ country
- Germany
- HQ region
- Europe
Offices20 records
Markets served
The Grunenthal Group business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Marketing or Sales, Supply Chain, Operations, Infrastructure
Revenue model
- Pharmaceutical Product Sales: Grünenthal generates revenue primarily through the sale of proprietary and established pharmaceutical products across its portfolio of pain management and related disease treatments. The company operates a fully integrated model from R&D through commercialization.
- Licensing and Royalty Revenue: Grünenthal licenses its products (Qutenza®, Nebido®) to regional partners in exchange for upfront payments, regulatory milestone payments, and margins or royalties on sales. Examples include BCWorld Pharm (South Korea), Clinect (Australia), and Apotex (Canada).
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | Multi-year contract | Pharmaceutical products sold through institutional and healthcare provider channels |
Go-to-market motion2 records
Distribution channels3 records
Marketing channels7 records
The Grunenthal Group product offering
Product offeringCore offering
Grünenthal is a science-based, fully integrated pharmaceutical company that develops, manufactures, and commercializes branded prescription medicines for pain management and related diseases, including Movantik® (naloxegol) for opioid-induced constipation, Qutenza® (capsaicin 8% patch) for peripheral neuropathic pain, and Nebido® (testosterone undecanoate) for male hypogonadism, while advancing a proprietary NaV 1.8 inhibitor pipeline for non-opioid pain therapy. The company grows through M&A of established brands and direct commercial sales via 28 country affiliates serving approximately 100 countries.
Product overview
Grünenthal is a science-based, privately-owned pharmaceutical company and global leader in pain management. The company operates as a fully integrated pharmaceutical organization offering established pain medications alongside an active R&D pipeline focused on non-opioid therapies. Key products include Movantik® (naloxegol) for opioid-induced constipation, Qutenza® for peripheral neuropathic pain, and Nebido® for testosterone replacement. Grünenthal acquired Valinor Pharma in 2024 for approximately $250 million, gaining global rights to Movantik®, and took full ownership of the Grünenthal Meds portfolio (12 established brands across 6 therapeutic areas) in 2026. The company's innovation pipeline includes a proprietary NaV 1.8 inhibitor currently in Phase I trials for non-opioid pain therapy and Tegacorat (GRM-01). Products are available in approximately 100 countries, with commercial operations spanning Europe, Latin America, and the United States through 28 country affiliates.
Differentiator
Problem solved
Functional benefit
Brands
- Grünenthal PRO: Full-service CMO service offering
- Grünenthal Health
Products and services
- Movantik® (naloxegol) Oral medication for the treatment of opioid-induced constipation (OIC) in adult patients with chronic non-cancer pain. Generated over $200 million in US sales in 2023 and is sold to healthcare providers and pain specialists globally through Grünenthal's commercial affiliates.
- Qutenza® (capsaicin 8% topical patch) Topical non-systemic, non-opioid patch indicated for the management of peripheral neuropathic pain. Applied by healthcare professionals and pain specialists in clinical settings; licensed to regional distribution partners in select markets.
- Nebido® (testosterone undecanoate) Long-acting injectable testosterone replacement therapy for male hypogonadism. Out-licensed to regional partners in selected markets.
- Grünenthal Meds portfolio Portfolio of 12 established brands across six therapeutic areas available in over 60 markets, providing a diversified specialty pharma commercial platform.
- NaV 1.8 inhibitor (proprietary investigational program) Proprietary, orally administered, voltage-gated sodium channel (NaV) 1.8 inhibitor being developed as a non-opioid therapy option across a range of acute and chronic pain conditions. Currently in Phase I clinical development.
- Tegacorat (GRM-01) Pipeline asset referenced in the Tegacorat digital library section of Grünenthal's science website, associated with the company's research in pain-adjacent indications and Duchenne muscular dystrophy.
Quantifiable outcome
- Movantik® generated over $200 million in US sales in 2023 following Valinor Pharma's commercial innovations.
- +2 more outcomes
Companies that use The Grunenthal Group
Customer profileNamed customers3 records
Segments3 records
Ideal customer profiles2 records
The Grunenthal Group technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature3 records
The Grunenthal Group partnerships and signals
Strategic signalPartnerships
Six partnerships are on record, tiered regional and core.
- BCWorld PharmregionalGrünenthal and BCWorld Pharm entered into an agreement granting BCWP exclusive rights to market Qutenza® in South Korea. Grünenthal will receive payments upon regulatory approval and sales, with BCWP responsible for obtaining marketing authorization and distribution.
- Kyowa Kirin InternationalcoreGrünenthal acquired Kyowa Kirin International's 49% stake in the 'Grünenthal Meds' joint venture, taking full ownership of the portfolio and operations. The joint venture was established in 2023 and comprised a portfolio of 12 established brands across six therapeutic areas and over 60 markets. Integration was expected to be completed by June 2026.
- Clinect Pty LtdregionalGrünenthal granted Clinect exclusive Australian rights to Qutenza®, a topical non-systemic, non-opioid patch for peripheral neuropathic pain. Clinect handles marketing authorization and distribution in Australia, a major Asia-Pacific market. This aligns with Grünenthal's strategy to expand Qutenza®'s global footprint.
- Apotex Inc. / Searchlight PharmaregionalGrünenthal and Apotex entered into a licensing agreement granting Apotex exclusive Canadian rights to Nebido® (testosterone undecanoate), a long-acting injectable testosterone replacement therapy for male hypogonadism. Apotex's branded division Searchlight Pharma will pursue regulatory approval and market and distribute the product in Canada. Grünenthal receives upfront payment, regulatory milestone payments, and a margin on sales.
- Apotex Inc. / Searchlight PharmaregionalGrünenthal granted Apotex exclusive Canadian rights to Qutenza®, a topical non-systemic, non-opioid pain patch for neuropathic pain management. Apotex's specialty division Searchlight Pharma will pursue regulatory approval and market the product in Canada, with Grünenthal receiving upfront, regulatory milestone, and royalty payments.
- Valinor Pharma (Acquisition)coreGrünenthal acquired US-based Valinor Pharma in an all-stock deal valued at approximately $250 million, gaining global ownership of Movantik® (naloxegol) for opioid-induced constipation. Valinor had improved Movantik's commercial platform, leading to 150% revenue increase in Q1 2024 and record EBITDA. The deal enhances Grünenthal's presence in the US pain management market.
Scale indicators6 records
Recent moves6 records
Expansion highlights6 records
The Grunenthal Group competitors and assessment
Company assessmentDirect peers
- Vertex Pharmaceuticals: Vertex's Journavx (suzetrigine) is a recently approved non-opioid pain therapy, making Vertex the most direct competitor in novel pain mechanisms. Both companies target the same unmet need for non-opioid analgesics with proprietary R&D pipelines.
- Collegium Pharmaceutical: US specialty pharma focused on pain management with established branded products (Xtampza, Nucynta). Comparable mid-sized pain-focused commercial model targeting similar prescriber base of pain specialists.
- Purdue Pharma: Private pain-focused pharmaceutical company with similar legacy in pain therapeutics and pivot toward non-opioid approaches. Directly comparable in therapeutic focus, though currently operating under Chapter 11 restructuring.
- Endo International: Specialty pharma with pain management franchise including products for neuropathic and chronic pain. Operates a similar branded-pain model targeting prescribers in the same therapeutic area.
Emerging players
- Cara Therapeutics: Clinical-stage biopharma developing novel pain and pruritus therapeutics, including Korsuva (difelikefalin). Comparable in therapeutic focus on pain-adjacent indications with a smaller, more pipeline-driven profile.
- Scilex Holding: Specialty pharma focused on non-opioid pain management with ZTlido (lidocaine patch) and Sprix/ELYXYB. Smaller and earlier-stage than Grünenthal but directly comparable in non-opioid pain commercial model.
- Jazz Pharmaceuticals: Specialty pharma with growing neuroscience and pain presence including Xywav for narcolepsy and emerging pain assets. Mid-cap peer with comparable focus on CNS/pain-adjacent therapeutics.
Broad incumbents
- Teva Pharmaceutical Industries: Global generic and specialty pharma with a meaningful pain franchise (including Ajovy for migraine). Overlaps in pain therapeutics but operates across far broader therapeutic areas.
- Pfizer: One of the largest global pharma companies with established pain and neuroscience franchises. Competes broadly in the same therapeutic categories but at much greater scale and across all major indications.
- Eli Lilly: Major pharma with significant pain and migraine portfolio (Emgality, Reyvow) and active neuroscience pipeline. Larger incumbent operating across multiple therapeutic areas including pain.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat6 records
Key risks5 records
Key highlights7 records
Customer concentration
The Grunenthal Group social profiles
Digital presenceThe Grunenthal Group financial estimates
Financial estimateRevenue estimate
Valuation estimate
The Grunenthal Group leadership team
Management profileNumber of profiles
Profiles14 records
The Grunenthal Group subsidiaries and ownership
Company hierarchySubsidiaries12 records
The Grunenthal Group funding detail
Funding detailFunding overview
Funding rounds3 records
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
The Grunenthal Group M&A and investment
M&A and investmentM&A6 records
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about The Grunenthal Group
What does The Grunenthal Group do?
Grünenthal is a science-based, fully integrated pharmaceutical company that develops, manufactures, and commercializes branded prescription medicines for pain management and related diseases, including Movantik® (naloxegol) for opioid-induced constipation, Qutenza® (capsaicin 8% patch) for peripheral neuropathic pain, and Nebido® (testosterone undecanoate) for male hypogonadism, while advancing a proprietary NaV 1.8 inhibitor pipeline for non-opioid pain therapy. The company grows through M&A of established brands and direct commercial sales via 28 country affiliates serving approximately 100 countries.
Is The Grunenthal Group a public or private company?
The Grunenthal Group is a private company. It is classified as family owned and is currently operating.
When was The Grunenthal Group founded?
The Grunenthal Group was founded in 1946. It employs 1,001 to 5,000 people.
Where is The Grunenthal Group based?
The Grunenthal Group is headquartered in Aachen, Germany, in the Europe region.
How does The Grunenthal Group make money?
Two revenue lines are on record. Pharmaceutical Product Sales are the primary driver. The others are licensing and Royalty Revenue.
Who are The Grunenthal Group's main competitors?
Direct peers on record are Vertex Pharmaceuticals, Collegium Pharmaceutical, Purdue Pharma and Endo International. Emerging players are Cara Therapeutics, Scilex Holding and Jazz Pharmaceuticals. Broad incumbents are Teva Pharmaceutical Industries, Pfizer and Eli Lilly.
Does The Grunenthal Group have an API?
No public API is recorded for The Grunenthal Group.
What industry is The Grunenthal Group in?
The Grunenthal Group's product category is Pain Management Pharmaceuticals. Its primary akta.pro industry code is HLAIAAAN, Pain Management & Anesthesiology Pharmaceuticals, with a secondary code of HLAKAIAM, Pain Medicine (Interventional/Neuropathic Pain). Its NAICS code is 325412 and its SIC code is 2834.